102137-66-6

Basic information

• Product Name: (4-Benzyloxy-3-methyl-pyridin-2-yl)-methanol
• Synonyms: (4-Benzyloxy-3-methyl-pyridin-2-yl)-methanol
• CAS NO: 102137-66-6
• Molecular Weight: 229.279
• Mol File: 102137-66-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (4-Benzyloxy-3-methyl-pyridin-2-yl)-methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (4-Benzyloxy-3-methyl-pyridin-2-yl)-methanol(102137-66-6)
• EPA Substance Registry System: (4-Benzyloxy-3-methyl-pyridin-2-yl)-methanol(102137-66-6)

Safety Data

• Hazardous Substances Data: 102137-66-6(Hazardous Substances Data)

Upstream product

• 102127-30-0 Acetic acid 4-benzyloxy-3-methyl-pyridin-2-ylmethyl ester 
• 100-51-6 benzyl alcohol 
• 59886-90-7 4-chloro-2,3-dimethylpyridine-N-oxide 
• 22710-07-2 2,3-dimethylpyridine 1-oxide 
• 583-61-9 2,3-Lutidine 
• 102127-29-7 4-(benzyloxy)-2,3-dimethylpyridin-N-oxide 
• 37699-43-7 2,3-dimethyl-4-nitropyridine N-oxide 

Downstream Products

• 768319-30-8 4-Benzyloxy-2-chloromethyl-3-methyl-pyridine 

Relevant articles and documents

ARYL HYDROCARBON RECEPTOR LIGANDS AND THEIR ANALOGUES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISORDERS

Aryl hydrocarbon receptor (AHR) agonists and their use in treating or preventing or reducing the risk of an inflammatory disorder associated with a reduced expression of an aryl hydrocarbon receptor (AHR), including necrotizing enterocolitis, for preventing, reducing the risk of, or reducing the severity of an inflammatory disorder associated with a reduced expression of an aryl hydrocarbon receptor (AHR), and as an additive to infant nutritional formulas.

Structure-activity relationship of 2-[[(2-Pyridyl)methyl]thio]-1H- benzimidazoles as anti Helicobacter pylori agents in vitro and evaluation of their in vivo efficacy

A relationship between the structure of 21 2-[[(2-pyridyl)methyl]thio]- 1H-benzimidazoles (6) and their anti Helicobacter pylori activity expressed as minimum bactericidal concentration (MBC) values is described. Observed MBCs ranged from 256 to 1 μg/mL. The structure - activity relationship (SAR) showed that larger and more lipophilic compounds, especially compounds with such substituents in the 4-position of the pyridyl moiety, generally had lower MBC values. Four new compounds 'that were predicted to be potent by the established SAR model were synthesized and tested. One such compound, i.e., 2-[[(4-[(cyclopropylmethyl)oxy]3-methyl-2-pyridyl)methyl]thio]-1H- benzimidazole (18), was tested for in vivo efficacy in a mouse Helicobacter felis model (125 μmol/kg bid given orally for 4 days, n = 4). Unfortunately, antibacterial activity could not be clearly demonstrated in this model. Instead a potent acid secretion inhibition was observed. This finding was attributed to the methylthio compound being oxidized to the corresponding methyl sulfinyl derivative, i.e., a proton pump inhibitor, in vivo. Although the antibacterial activity had the potential of decreasing H. felis cell counts in vivo the proton pump inhibitory effect became dominant and actually promoted H. felis cell growth. Hence, we conclude that the antibacterial utility of the 2-[[(2-pyridyl)methyl]thio]1H-benzimidazoles (6) as a compound class is compromised by their propensity to become proton pump inhibitors upon metabolic oxidation in vivo.